Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.06B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.25M in total
- 1
- 13F holdersQ2 2026, +19 vs. previous quarter
- 208
- 13F valueReported value at the end of Q2 2026
- $2.06B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TSHA, Q2 2026
No superinvestor reported holding TSHA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Taysha Gene Therapies, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)6:54 PM ET | Jul 10 | Same day | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $6.24 | −$1.25M | −17.6%936.4K after | 10b5-1 |
| Apr 13, 2026 (view filing) | Apr 10 | 3 days | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $4.46 | −$892.0K | −15.0%1.14M after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Alam KamranCHIEF FINANCIAL OFFICER | SSale | −1.66K | $4.52 | −$7.48K | −0.1%1.44M after | |
| Jan 27, 2026 (view filing) | Jan 23-26 | 4 days | Alam KamranCHIEF FINANCIAL OFFICER | SSale | −102.8K | $4.72 | −$485.0K | −6.6%1.44M after | 2 lots |
| Jan 27, 2026 (view filing) | Jan 23-26 | 4 days | Nagendran SukumarPresident and Head of R&D | SSale | −116.0K | $4.72 | −$547.5K | −8.1%1.32M after | 2 lots |
| Jan 27, 2026 (view filing) | Jan 23-26 | 4 days | Nolan Sean P.Chief Executive Officer | SSale | −178.1K | $4.72 | −$840.2K | −5.8%2.91M after | 2 lots |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $4.71 | −$942.0K | −16.6%1.01M after | 10b5-1 |
| Dec 1, 2025 (view filing) | Nov 28-Dec 1 | 3 days | Nagendran SukumarPresident and Head of R&D | SSale | −370.2K | $4.58 | −$1.70M | −26.9%1.01M after | 2 lots |
| Sep 12, 2025 (view filing) | Sep 10 | 2 days | Nagendran SukumarPresident and Head of R&D | SSale | −200.0K | $3.23 | −$646.0K | −16.6%1.01M after | 10b5-1 |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Nagendran SukumarPresident and Head of R&D | SSale | −57.1K | $2.85 | −$162.6K | −4.7%1.17M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Taysha Gene Therapies, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | $162.7M | 1.46% | +2,188,888+10.1% | Added |
| Ra Capital Management, L.P. | 23,555,648 | $160.4M | 1.39% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 22,713,118 | $154.7M | 0.02% | +343,473+1.5% | Added |
| BlackRock, Inc. | 20,691,927 | $140.9M | 0.00% | +2,326,319+12.7% | Added |
| Vestal Point Capital, LP | 19,415,000 | $132.2M | 3.09% | +1,415,000+7.9% | Added |
| Morgan Stanley | 16,487,479 | $112.3M | 0.01% | −1,477,892−8.2% | Reduced |
| RTW Investments, LP | 13,560,258 | $92.3M | 0.79% | −119,990−0.9% | Reduced |
| FMR LLC | 13,336,413 | $90.8M | 0.00% | −984,842−6.9% | Reduced |
| Vanguard Capital Management LLC | 12,478,595 | $85.0M | 0.00% | +2,247,093+22.0% | Added |
| State Street Corp | 11,421,920 | $77.8M | 0.00% | +212,842+1.9% | Added |